Bone News and Research

RSS

New mathematical model may hasten drug development for Parkinson's Disease

Australian scientists have significantly advanced our understanding of dopamine release from nerve cells, findings that should speed the development of more effective drugs for treating Parkinson's Disease.

19 Nov 2009

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.

18 Nov 2009

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body.

18 Nov 2009

Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced

Poniard Pharmaceuticals, Inc. today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC).

18 Nov 2009

FaceBase Consortium established to create encyclopedic database on facial birth defects

Researchers at the University of Pittsburgh and the University of Iowa will lead a $9 million, five-year initiative to study the cause of facial birth defects. The FaceBase Consortium will create an encyclopedic database of how the faces of children develop and what goes wrong to cause malformations.

18 Nov 2009

Phase III randomized clinical trial for Alpharadin to be commenced

International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide.

18 Nov 2009

New encapsulated system may enable doctors to deliver anti-cancer drugs directly to tumors

An encapsulation breakthrough by researchers at the Technion-Israel Institute of Technology may enable doctors to deliver anti-cancer drugs directly to tumors over extended periods of time, while preventing the systemic side effects of chemotherapy and other current cancer treatments.

18 Nov 2009

FDA approval to market KRYPTONITE Bone Cement received

Doctors Research Group, Inc. announced today that it has received 510(k) approval from the U.S. Food and Drug Administration (FDA) to market KRYPTONITE(TM) Bone Cement for cranioplasty applications.

18 Nov 2009

Medtronic introduces new TSRH 3Dx Spinal System to address multiple pathologies

Medtronic, Inc., today announced the launch of the TSRH® 3Dx™ Spinal System. Designed with procedural efficiency in mind, the TSRH 3Dx Spinal System offers two screws designed to address multiple pathologies.

17 Nov 2009

CONMED Linvatec produces the smallest Biocomposite Interference screw for fixation of ACL and PCL grafts

CONMED Corporation's CONMED Linvatec arthroscopy unit today announced the release of new sizes of its Matryx™ Biocomposite Interference Screw. These new screws represent the latest advance in biocomposite material technology that allows CONMED Linvatec to produce the smallest Biocomposite Interference screw available on the market today for primary fixation of ACL and PCL grafts.

17 Nov 2009

Cancer pain drug market to be $3.7 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the continued dominance of opioids that include immediate-release morphine and novel fast acting opioid reformulations, the cancer pain drug market will increase from $2.3 billion in 2008 to $3.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

17 Nov 2009

Advanced BioMedical Technologies commences animal tests with novel patented PA bio-absorbable material

Advanced BioMedical Technologies Inc. announced that the Company's subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd., has signed a cooperative agreement with The First Affiliated Hospital of Guangdong Pharmaceutical University ("GDPU Hospital") in Guangzhou. Under this cooperative agreement, both parties will join efforts in conducting research and animal tests on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction utilizing ABT-CHANGHUA's novel patented PA (Polyamide) bio-absorbable material.

17 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

Phase II clinical study to evaluate Nanocort commenced

Galapagos NV announced today that it has started a Phase II clinical study to evaluate Nanocort's effectiveness in treating flares in multiple sclerosis (MS). Nanocort combines less frequent treatment with lower dosage and potentially more effective delivery than other MS flare treatments.

17 Nov 2009

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases, particularly ALS and Parkinson’s disease, was found to have a positive effect in a mouse model of multiple sclerosis (MS).

16 Nov 2009

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.

16 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

Onyx Pharmaceuticals acquires Proteolix

Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.

16 Nov 2009

Myeloma UK launches innovative clinical trial network

Yorkshire myeloma patients are set to be among the first to benefit from an innovative Myeloma Clinical Trial Network launched by Myeloma UK.

16 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

Bone News and Research

New mathematical model may hasten drug development for Parkinson's Disease

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced

FaceBase Consortium established to create encyclopedic database on facial birth defects

Phase III randomized clinical trial for Alpharadin to be commenced

New encapsulated system may enable doctors to deliver anti-cancer drugs directly to tumors

FDA approval to market KRYPTONITE Bone Cement received

Medtronic introduces new TSRH 3Dx Spinal System to address multiple pathologies

CONMED Linvatec produces the smallest Biocomposite Interference screw for fixation of ACL and PCL grafts

Cancer pain drug market to be $3.7 billion in 2018

Advanced BioMedical Technologies commences animal tests with novel patented PA bio-absorbable material

Genentech submits sBLAs to the FDA for Avastin

Phase II clinical study to evaluate Nanocort commenced

BrainStorm Cell's therapeutic approach has potential for treatment of neurodegenerative diseases

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Onyx Pharmaceuticals acquires Proteolix

Myeloma UK launches innovative clinical trial network

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News